vs

Side-by-side financial comparison of BioNexus Gene Lab Corp (BGLC) and Iveda Solutions, Inc. (IVDA). Click either name above to swap in a different company.

Iveda Solutions, Inc. is the larger business by last-quarter revenue ($626.0K vs $483.8K, roughly 1.3× BioNexus Gene Lab Corp). BioNexus Gene Lab Corp runs the higher net margin — -214.2% vs -258.6%, a 44.4% gap on every dollar of revenue. On growth, Iveda Solutions, Inc. posted the faster year-over-year revenue change (-64.1% vs -80.8%). Over the past eight quarters, Iveda Solutions, Inc.'s revenue compounded faster (34.4% CAGR vs -54.9%).

BioNexus Gene Lab Corp is a biotechnology company specializing in molecular diagnostic testing, genetic analysis, and related life science solutions. It caters to healthcare institutions, research organizations, and individual customers, with its primary operational and market focus on the Southeast Asian region.

Iveda Solutions, Inc. is a technology provider specializing in cloud-based AI video surveillance, IoT-enabled smart sensing, and integrated smart city solutions. It serves public sector, enterprise, and education clients across North America and Asia, with core offerings covering remote security monitoring, smart facility management, and real-time data analysis tools for public safety use cases.

BGLC vs IVDA — Head-to-Head

Bigger by revenue
IVDA
IVDA
1.3× larger
IVDA
$626.0K
$483.8K
BGLC
Growing faster (revenue YoY)
IVDA
IVDA
+16.8% gap
IVDA
-64.1%
-80.8%
BGLC
Higher net margin
BGLC
BGLC
44.4% more per $
BGLC
-214.2%
-258.6%
IVDA
Faster 2-yr revenue CAGR
IVDA
IVDA
Annualised
IVDA
34.4%
-54.9%
BGLC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BGLC
BGLC
IVDA
IVDA
Revenue
$483.8K
$626.0K
Net Profit
$-1.0M
$-1.6M
Gross Margin
-0.8%
3.6%
Operating Margin
-213.5%
-262.7%
Net Margin
-214.2%
-258.6%
Revenue YoY
-80.8%
-64.1%
Net Profit YoY
-197.5%
-7.1%
EPS (diluted)
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BGLC
BGLC
IVDA
IVDA
Q4 25
$483.8K
$626.0K
Q3 25
$2.5M
$1.7M
Q2 25
$2.3M
$1.5M
Q1 25
$2.1M
$1.5M
Q4 24
$2.5M
$1.7M
Q3 24
$2.6M
$2.4M
Q2 24
$2.0M
$1.5M
Q1 24
$2.4M
$346.8K
Net Profit
BGLC
BGLC
IVDA
IVDA
Q4 25
$-1.0M
$-1.6M
Q3 25
$-709.0K
$-221.3K
Q2 25
$-616.2K
$-564.2K
Q1 25
$-623.3K
$-793.7K
Q4 24
$-348.3K
$-1.5M
Q3 24
$-1.3M
$-581.4K
Q2 24
$199.1K
$-599.0K
Q1 24
$-103.8K
$-1.3M
Gross Margin
BGLC
BGLC
IVDA
IVDA
Q4 25
-0.8%
3.6%
Q3 25
14.8%
31.3%
Q2 25
16.3%
29.1%
Q1 25
16.1%
19.5%
Q4 24
12.3%
11.9%
Q3 24
12.4%
17.1%
Q2 24
14.6%
32.7%
Q1 24
15.3%
52.5%
Operating Margin
BGLC
BGLC
IVDA
IVDA
Q4 25
-213.5%
-262.7%
Q3 25
-27.6%
-13.0%
Q2 25
-27.0%
-34.8%
Q1 25
-28.9%
-56.7%
Q4 24
-16.5%
-87.3%
Q3 24
-50.9%
-25.4%
Q2 24
13.1%
-39.7%
Q1 24
-3.3%
-384.1%
Net Margin
BGLC
BGLC
IVDA
IVDA
Q4 25
-214.2%
-258.6%
Q3 25
-27.9%
-13.4%
Q2 25
-27.3%
-36.9%
Q1 25
-29.2%
-53.8%
Q4 24
-13.8%
-86.7%
Q3 24
-51.1%
-24.2%
Q2 24
10.1%
-39.0%
Q1 24
-4.4%
-371.9%
EPS (diluted)
BGLC
BGLC
IVDA
IVDA
Q4 25
$-0.33
Q3 25
$-0.40
$-0.07
Q2 25
$-0.34
$-0.20
Q1 25
$-0.04
$-0.28
Q4 24
$0.55
$-0.60
Q3 24
$-0.75
$-0.27
Q2 24
$0.11
$-0.30
Q1 24
$-0.01
$-0.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BGLC
BGLC
IVDA
IVDA
Cash + ST InvestmentsLiquidity on hand
$2.5M
$5.2M
Total DebtLower is stronger
$393.4K
Stockholders' EquityBook value
$8.6M
$4.8M
Total Assets
$9.3M
$6.4M
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BGLC
BGLC
IVDA
IVDA
Q4 25
$2.5M
$5.2M
Q3 25
$3.3M
Q2 25
$1.6M
Q1 25
$2.5M
Q4 24
$2.9M
$2.6M
Q3 24
$3.6M
Q2 24
$2.9M
Q1 24
$3.9M
Total Debt
BGLC
BGLC
IVDA
IVDA
Q4 25
$393.4K
Q3 25
$306.4K
Q2 25
$365.3K
Q1 25
$340.8K
Q4 24
$376.2K
Q3 24
$545.9K
Q2 24
$564.0K
Q1 24
$480.0K
Stockholders' Equity
BGLC
BGLC
IVDA
IVDA
Q4 25
$8.6M
$4.8M
Q3 25
$6.8M
$3.8M
Q2 25
$7.5M
$1.5M
Q1 25
$7.8M
$1.7M
Q4 24
$8.3M
$2.5M
Q3 24
$9.4M
$4.1M
Q2 24
$9.5M
$2.8M
Q1 24
$9.3M
$3.3M
Total Assets
BGLC
BGLC
IVDA
IVDA
Q4 25
$9.3M
$6.4M
Q3 25
$7.6M
$5.8M
Q2 25
$9.4M
$4.4M
Q1 25
$9.5M
$4.5M
Q4 24
$10.4M
$5.2M
Q3 24
$11.0M
$9.1M
Q2 24
$11.1M
$6.8M
Q1 24
$11.2M
$6.6M
Debt / Equity
BGLC
BGLC
IVDA
IVDA
Q4 25
0.08×
Q3 25
0.08×
Q2 25
0.25×
Q1 25
0.20×
Q4 24
0.15×
Q3 24
0.13×
Q2 24
0.20×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BGLC
BGLC
IVDA
IVDA
Operating Cash FlowLast quarter
$961.1K
$-252.4K
Free Cash FlowOCF − Capex
$960.1K
FCF MarginFCF / Revenue
198.5%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BGLC
BGLC
IVDA
IVDA
Q4 25
$961.1K
$-252.4K
Q3 25
$-1.2M
$-317.0K
Q2 25
$-737.9K
$-1.3M
Q1 25
$-824.1K
$-126.0K
Q4 24
$219.2K
$-889.8K
Q3 24
$-1.6M
$-1.2M
Q2 24
$-672.3K
$-999.7K
Q1 24
$-37.2K
$-1.3M
Free Cash Flow
BGLC
BGLC
IVDA
IVDA
Q4 25
$960.1K
Q3 25
$-1.2M
Q2 25
$-759.4K
Q1 25
$-833.1K
Q4 24
$215.2K
$-889.8K
Q3 24
$-1.8M
$-1.5M
Q2 24
$-674.1K
$-1.1M
Q1 24
$-59.1K
$-1.5M
FCF Margin
BGLC
BGLC
IVDA
IVDA
Q4 25
198.5%
Q3 25
-48.9%
Q2 25
-33.6%
Q1 25
-39.0%
Q4 24
8.5%
-51.1%
Q3 24
-68.5%
-64.1%
Q2 24
-34.1%
-72.6%
Q1 24
-2.5%
-427.3%
Capex Intensity
BGLC
BGLC
IVDA
IVDA
Q4 25
0.2%
Q3 25
0.2%
Q2 25
0.9%
Q1 25
0.4%
Q4 24
0.2%
0.0%
Q3 24
7.6%
12.5%
Q2 24
0.1%
7.5%
Q1 24
0.9%
54.3%
Cash Conversion
BGLC
BGLC
IVDA
IVDA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-3.38×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons